serum level of IgA, IgG, IgM, CA125, CEA, migration inhibitory factor-related protein 14 (MRP14), stromal cell-derived factor 1 (SDF-1), fibroblast-specific protein 1 (FSP-1), and C-X-C Motif Chemokine Receptor 4 (CXCR4) in gastric cancer after treatment
serum markers in gastric cancer
Abstract
Objective: The current study was undertaken to assess the effects of the treatment on ( IgA, IgG, IgM, CA125, CEA, migration inhibitory factor-related protein 14 (MRP14), stromal cell-derived factor 1 (SDF-1), fibroblast-specific protein 1 (FSP-1), and C-X-C Motif Chemokine Receptor 4 (CXCR4) in patients with advanced gastric cancer.
Methods: In this randomized clinical trial, 100 patients with gastric cancer were recruited after excluding 8 ineligible cases and assigned to receive either oxaliplatin (reference group) or the SOX regimen (observation group) via random number table method at a ratio of 1:1, with 50 patients in each group. The primary clinical endpoint was clinical efficacy, and secondary endpoints included immune function, tumor markers, and chemotherapy toxicities.
Results: The SOX regimen was associated with significantly higher clinical efficacy versus oxaliplatin monotherapy, as indicated by the higher disease control rate and objective remission rate (P<0.05). The SOX regimen provided better immunity recovery of patients versus oxaliplatin alone, evidenced by the higher levels of immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), CD3+, CD4+ and natural killer (NK) cells and lower CD8+ levels in the observation group (P<0.05). The SOX regimen provided markedly higher anti-tumor benefits than oxaliplatin monotherapy, evinced by the significantly reduced serum concentrations of tumor markers, including cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), migration inhibitory factor-related protein 14 (MRP14), stromal cell-derived factor 1 (SDF-1), fibroblast-specific protein 1 (FSP-1), and C-X-C Motif Chemokine Receptor 4 (CXCR4) (P<0.05). The SOX regimen was associated with a higher safety profile versus single oxaliplatin by reducing the occurrence of nausea and vomiting and leukopenia in patients (P<0.05).
Conclusion: The SOX regimen provides a viable treatment alternative for advanced gastric cancer management with favorable clinical efficacy. It enhances immune function, reduces tumor marker concentrations and toxic side effects of chemotherapy, and offers substantial prognostic benefits.
References
2. Yamashita, K., et al., History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg, 2021. 5(4): p. 446-456.
3. Saito, S., et al., Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases. Ann Surg Oncol, 2021. 28(7): p. 3863-3870.
4. Yagi, S., et al., Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer. Glob Health Med, 2021. 3(1): p. 31-36.
5. Yamada, Y., et al., Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol, 2015. 26(1): p. 141-148.
6. Zhong, D.T., et al., Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer. Pathol Oncol Res, 2015. 21(4): p. 867-73.
7. Jiang, D., et al., Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review. Front Pharmacol, 2020. 11: p. 1027.
8. Koizumi, W., et al., Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol, 2010. 21(5): p. 1001-5.
9. Yamada, Y., Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan. Glob Health Med, 2020. 2(3): p. 156-163.
10. Boku, N., et al., Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol, 2019. 30(2): p. 250-258.
11. Xu, R., et al., Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther, 2013. 6: p. 925-9.
12. Yu, J., et al., Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open, 2022. 5(2): p. e220426.
13. Bin, Y., et al., SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. Trials, 2022. 23(1): p. 211.
14. Kawakami, K., et al., The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer. Biol Pharm Bull, 2021. 44(8): p. 1075-1080.
15. Li, Z., et al., Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer. Oncol Lett, 2017. 14(1): p. 579-586.
16. Xu, D., et al., Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer. J buon, 2021. 26(3): p. 932-939.
17. Tang, W., et al., Clinical significance of CD8(+) T cell immunoreceptor with Ig and ITIM domains(+) in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. Oncoimmunology, 2019. 8(6): p. e1593807.
18. Wang, X., et al., The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer, 2021. 21(1): p. 20.
19. Zhang, X., et al., Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Cancer Manag Res, 2020. 12: p. 6641-6653.
20. Xue, K., et al., Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial. Chin J Cancer Res, 2018. 30(5): p. 516-525.
Copyright (c) 2025 Yufeng Ni
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.